MTD — Mettler-Toledo International, I

Is MTD overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Diagnostics & Research

Overbought As of November 17, 2026

Mettler-Toledo International, I (MTD) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Diagnostics & Research) last closed at $1727.26. The rating moved from Neutral to Overbought on November 6, 2026.

See all overbought Healthcare stocks →

AI analysis

Mettler‑Toledo International, I (MTD) combines a durable installed base of precision instruments with recurring consumables and high‑margin service revenue, producing strong cash flow and a healthy balance sheet. The company benefits from secular growth in life sciences, pharma/biopharma R&D and quality control spending; recent sector strength in large‑cap pharma and biopharma investment trends is a constructive readthrough for instrument demand. Near term, performance will track order momentum and capital expenditure patterns in end markets, while longer‑term upside depends on continued adoption of automation, expansion of service and consumable revenue, and selective acquisitions. Key vulnerabilities include valuation sensitivity to cyclical capital spending, FX and supply chain risks, and competitive pricing pressure. Limited social sentiment and filing updates create some information asymmetry in the short term.

Key factors

  • Leading market position in precision instruments and laboratory balances with strong brand and installed base that drives recurring consumables and service revenue
  • Consistent high gross and operating margins historically and strong free cash flow generation supporting reinvestment and dividend/repurchases
  • Exposure to secular growth in life sciences, pharmaceutical/biopharma R&D and quality control in regulated industries driving demand for instruments and automation
  • Favorable readthrough from healthcare/pharma strength (ongoing obesity/GLP‑1 expansion and pharma M&A) supporting biopharma capex and instrument purchases
  • Prudent balance sheet with capacity to invest in product development, services expansion and tuck‑in acquisitions to bolster specialty capabilities

Risks

  • Premium valuation leaving shares sensitive to multiple compression if macro or industrial capex weakens
  • Cyclicality of capital equipment spending: extended slowdown in pharma, industrial or lab budgets would reduce orders and lengthen sales cycles
  • Foreign exchange exposure and supply‑chain disruptions that can pressure margins and delivery timelines
  • Competitive pressures from other instrument and automation vendors and potential pricing pressure in some end markets
  • Limited social media/research signal and lack of immediate filing updates increases near‑term information risk

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for MTD — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.